Leerink Partners analyst Thomas Smith maintained a Buy rating on Aclaris Therapeutics (NASDAQ:ACRS) on Friday, setting a price target of $26, which is approximately 22.41% above the present share price of $21.24.
Smith expects Aclaris Therapeutics to post earnings per share (EPS) of -$0.57 for the second quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Aclaris Therapeutics, with an average price target of $33.
The analysts price targets range from a high of $40 to a low of $26.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.78 million and a net profit of -$12.09 million. The company's market cap is $1.11 billion.
According to TipRanks.com, Leerink Partners analyst Thomas Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.3% and a 26.53% success rate.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.